Abstract
Food allergy is increasing in prevalence in westernized countries, leading to significant morbidity including nutritional deficiencies and growth delay as well as psychosocial burdens and the potential for fatal anaphylaxis. There is currently no effective form of therapy, and the mainstay of treatment remains strict avoidance. However, there are a number of promising therapeutic strategies currently being investigated for the treatment of food allergies. Allergen-specific approaches, such as various forms of immunotherapy, have been a major focus of investigation and appear to be promising methods of desensitization. More recently, the addition of anti-IgE monoclonal antibodies (mAbs) to immunotherapy regimens has been studied. Early work with antigen-fixed leukocytes in a murine model has shown promise in inducing tolerance, as have vaccines containing modified recombinant food proteins coadministered with heat-killed Escherichia coli. Nonspecific approaches include a Chinese herbal formulation, anti-IgE mAbs, and Trichuris suis ova therapy. The array of treatment modalities currently being investigated increases the likelihood of finding one or more effective therapies for the treatment of food allergy.
Similar content being viewed by others
References
Branum AM, Lukacs SL (2009) Food allergy among children in the United States. Pediatrics 124(6):1549–1555
Rona RJ et al (2007) The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol 120(3):638–646
Branum AM, Lukacs SL (2008) Food allergy among U.S. children: trends in prevalence and hospitalizations. NCHS Data Brief. (10):1–8
Sicherer SH et al (2010) US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 125(6):1322–1326
Sicherer SH, Sampson HA (2007) Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol 120(3):491–503, quiz 504-5
Decker WW et al (2008) The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 122(6):1161–1165
Gupta R et al (2007) Time trends in allergic disorders in the UK. Thorax 62(1):91–96
Bock SA, Munoz-Furlong A, Sampson HA (2007) Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 119(4):1016–1018
Christie L et al (2002) Food allergies in children affect nutrient intake and growth. J Am Diet Assoc 102(11):1648–1651
Mennella JA, Ventura AK, Beauchamp GK (2011) Differential growth patterns among healthy infants fed protein hydrolysate or cow-milk formulas. Pediatrics 127(1):110–118
Lieberman JA, Sicherer SH (2011) Quality of life in food allergy. Curr Opin Allergy Clin Immunol 11(3):236–242
Flokstra-de Blok BM et al (2010) Health-related quality of life of food allergic patients measured with generic and disease-specific questionnaires. Allergy 65(8):1031–1038
Lieberman JA et al (2010) Bullying among pediatric patients with food allergy. Ann Allergy Asthma Immunol 105(4):282–286
Boyce JA et al (2010) Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 126(6 Suppl):S1–S58
Burks AW et al (2011) NIAID-sponsored 2010 guidelines for managing food allergy: applications in the pediatric population. Pediatrics 128(5):955–965
Nowak-Wegrzyn A, Sampson HA (2011) Future therapies for food allergies. J Allergy Clin Immunol 127(3):558–573, quiz 574-5
Burks AW, Laubach S, Jones SM (2008) Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol 121(6):1344–1350
Chehade M, Mayer L (2005) Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 115(1):3–12, quiz 13
Sicherer SH, Sampson HA (2010) Food allergy. J Allergy Clin Immunol 125(2 Suppl 2):S116–S125
Untersmayr E, Jensen-Jarolim E (2008) The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol 121(6):1301–1308, quiz 1309-10
Pali-Scholl I et al (2008) Anti-acids lead to immunological and morphological changes in the intestine of BALB/c mice similar to human food allergy. Exp Toxicol Pathol 60(4–5):337–345
Groschwitz KR, Hogan SP (2009) Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 124(1):3–20, quiz 21-2
Manicassamy S et al (2010) Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 329(5993):849–853
Navuluri L et al (2006) Allergic and anaphylactic response to sesame seeds in mice: identification of Ses i 3 and basic subunit of 11 s globulins as allergens. Int Arch Allergy Immunol 140(3):270–276
Fox AT et al (2009) Household peanut consumption as a risk factor for the development of peanut allergy. J Allergy Clin Immunol 123(2):417–423
Lack G (2012) Update on risk factors for food allergy. J Allergy Clin Immunol,
Brown SJ et al (2011) Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 127(3):661–667
Vickery BP et al (2011) Mechanisms of immune tolerance relevant to food allergy. J Allergy Clin Immunol 127(3):576–584, quiz 585-6
Eifan AO, Shamji MH, Durham SR (2011) Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 11(6):586–593
Patriarca G et al (2003) Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 17(3):459–465
Varshney P et al (2011) A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127(3):654–660
Jones SM et al (2009) Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124(2):292–300, 300 e1-97
Kim EH et al (2011) Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 127(3):640–646 e1
Freeman J (1930) “Rush” inoculation. Lancet 1:744
Hunt KJ et al (1978) A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 299(4):157–161
Oppenheimer JJ et al (1992) Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90(2):256–262
Nelson HS et al (1997) Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99(6 Pt 1):744–751
Land MH, Kim EH, Burks AW (2011) Oral desensitization for food hypersensitivity. Immunol Allergy Clin North Am 31(2):367–376, xi
Scurlock AM et al (2010) Pediatric food allergy and mucosal tolerance. Mucosal Immunol 3(4):345–354
Schofield AT (1908) A case of egg poisoning. Lancet 1:716
Patriarca C et al (1984) Oral specific hyposensitization in the management of patients allergic to food. Allergol Immunopathol (Madr) 12(4):275–281
Bauer A et al (1999) Oral rush desensitization to milk. Allergy 54(8):894–895
Buchanan AD et al (2007) Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119(1):199–205
Staden U et al (2007) Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 62(11):1261–1269
Longo G et al (2008) Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. J Allergy Clin Immunol 121(2):343–347
Skripak JM et al (2008) A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol 122(6):1154–1160
Wood RA (2003) The natural history of food allergy. Pediatrics 111(6 Pt 3):1631–1637
Fleischer DM (2007) The natural history of peanut and tree nut allergy. Curr Allergy Asthma Rep 7(3):175–181
Clark AT et al (2009) Successful oral tolerance induction in severe peanut allergy. Allergy 64(8):1218–1220
Nadeau KC et al (2012) Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy. Immunol Allergy Clin North Am 32(1):111–133
Blumchen K et al (2010) Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 126(1):83–91 e1
Fisher HR, Toit GD, Lack G (2011) Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance? Arch Dis Child 96(3):259–264
Thyagarajan A et al (2010) Peanut oral immunotherapy is not ready for clinical use. J Allergy Clin Immunol 126(1):31–32
Durham SR et al (2012) SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 129(3):717–725 e5
Mempel M et al (2003) Severe anaphylaxis to kiwi fruit: immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 111(6):1406–1409
Enrique E et al (2005) Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 116(5):1073–1079
Fernandez-Rivas M et al (2009) Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64(6):876–883
Keet CA et al (2012) The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 129(2):448–455.e5
Otsu K, Fleischer DM (2012) Therapeutics in food allergy: the current state of the art. Curr Allergy Asthma Rep 12(1):48–54
Dupont C et al (2010) Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 125(5):1165–1167
Mondoulet L et al (2010) Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 40(4):659–667
Mondoulet L et al (2011) Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 154(4):299–309
MacGlashan DW Jr et al (1997) Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158(3):1438–1445
Pelaia G et al (2008) Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther Adv Respir Dis 2(6):409–421
Leung DY et al (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348(11):986–993
Kuehr J et al (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109(2):274–280
Casale TB et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117(1):134–140
Nadeau KC et al (2011) Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 127(6):1622–1624
Hofmann AM et al (2009) Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 124(2):286–291, 291 e1-6
Meglio P et al (2004) A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy 59(9):980–987
Smarr CB et al (2011) Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. J Immunol 187(10):5090–5098
Miller SD, Wetzig RP, Claman HN (1979) The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med 149(3):758–773
Luo X et al (2008) ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A 105(38):14527–14532
Li XM et al (2003) Persistent protective effect of heat-killed Escherichia coli producing “engineered”, recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 112(1):159–167
Li XM et al (2003) Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol 170(6):3289–3295
Chan CK et al (2006) Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-responsiveness in stabilized asthmatic children: a randomized, double-blind clinical trial. Pediatr Allergy Immunol 17(5):316–322
Chang TT, Huang CC, Hsu CH (2006) Clinical evaluation of the Chinese herbal medicine formula STA-1 in the treatment of allergic asthma. Phytother Res 20(5):342–347
Hsu CH, Lu CM, Chang TT (2005) Efficacy and safety of modified Mai-Men-Dong-Tang for treatment of allergic asthma. Pediatr Allergy Immunol 16(1):76–81
Kao ST et al (2000) The effect of Chinese herbal medicine, xiao-qing-long tang (XQLT), on allergen-induced bronchial inflammation in mite-sensitized mice. Allergy 55(12):1127–1133
Li XM, Brown L (2009) Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol 123(2):297–306, quiz 307-8
Bensky DBR (1990) Chinese herbal medicine: formulas & strategies. Eastland: Seattle.
Qu C et al (2007) Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy 37(6):846–855
Srivastava KD et al (2005) The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 115(1):171–178
Srivastava KD et al (2009) Food Allergy Herbal Formula-2 silences peanut-induced anaphylaxis for a prolonged posttreatment period via IFN-gamma-producing CD8+ T cells. J Allergy Clin Immunol 123(2):443–451
Patil SP et al (2011) Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: extended phase I study. J Allergy Clin Immunol 128(6):1259–1265 e2
Song Y et al (2010) Food allergy herbal formula 2 protection against peanut anaphylactic reaction is via inhibition of mast cells and basophils. J Allergy Clin Immunol 126(6):1208–1217 e3
Wang J et al (2010) Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 105(1):75–84
Sampson HA et al (2011) A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127(5):1309–1310 e1
Medeiros M Jr et al (2003) Schistosoma mansoni infection is associated with a reduced course of asthma. J Allergy Clin Immunol 111(5):947–951
Bashir ME et al (2002) An enteric helminth infection protects against an allergic response to dietary antigen. J Immunol 169(6):3284–3292
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published as part of the Special Issue on Food Allergy [34:6].
Rights and permissions
About this article
Cite this article
Henson, M., Burks, A.W. The future of food allergy therapeutics. Semin Immunopathol 34, 703–714 (2012). https://doi.org/10.1007/s00281-012-0319-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00281-012-0319-7